Table 1.
Clinicopathological Characteristics and MTFR2 Expression of Patients with Breast Cancer
| Variables | Number of Cases (%) |
|---|---|
| Age(years) | |
| ≤55 | 82(59.0%) |
| >55 | 57(41.0%) |
| Clinical stage | |
| I | 24(17.3%) |
| II | 79(56.8%) |
| III | 32(23.0%) |
| IV | 4(2.9%) |
| T classification | |
| T1 | 58(41.7%) |
| T2 | 68(48.9%) |
| T3 | 7(5.1%) |
| T4 | 6(4.3%) |
| N classification | |
| N0 | 63(45.3%) |
| N1 | 47(33.9%) |
| N2 | 15(10.8%) |
| N3 | 14(10.0%) |
| Grade | |
| I, II | 111(79.9%) |
| III | 28(20.1%) |
| Expression of ER | |
| Negative | 51(36.7%) |
| Positive | 88 (63.3%) |
| Expression of PR | |
| Negative | 61(43.9%) |
| Positive | 78(56.1%) |
| Expression of HER2 | |
| Negative | 105(75.5%) |
| Positive | 34(24.5%) |
| Expression of MTFR2 | |
| Low expression | 70(50.4%) |
| High expression | 69(49.6%) |
| Radiotherapy | |
| Not done | 96(69.1%) |
| Done | 43(30.9%) |
| Chemotherapy | |
| Not done | 41(29.5%) |
| Done | 98(70.5%) |